Full-year R&D expenses surged 17.9% to $124.0 million, while SG&A expenses fell 26.7%, reflecting a clear capital reallocation toward innovation. The Regeneron partnership provides crucial external validation for OPKO's ModeX MSTAR platform and includes an upfront payment, potential milestones exceeding $200 million per program, and tiered royalties. This positions OPKO as a development partner leveraging proprietary platform technologies with established pharma partners.
Cyborg Score Rationale
OPKO signed a Regeneron collaboration with potential milestones exceeding $200 million per program and overall value above $1 billion, and reported progress across multiple ModeX antibody programs. However, net loss widened to $225.7 million in 2025, and near-term profitability is challenged despite strong pipeline momentum and strategic partnerships providing external validation.
Top Insights
Management is actively reallocating capital away from the lower-margin diagnostics business and toward its high-potential pharmaceutical pipeline.
Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.
The FDA granted clearance to proceed to Phase 1 for its COVID-19 antibody, MDX2301, supported by non-dilutive funding from BARDA.
OPKO predicts 30% growth for fiscal 2026, a target that hinges on continued market penetration and effective sales execution of RAYALDEE.
Named Competitors
Regeneron Pharmaceuticals (REGN) — Strategic partner providing multispecific antibody binder technology and development expertise
Entera Bio — Technology partner providing N-Tab oral delivery platform for complex biologics
Quest Diagnostics / LabCorp — Competitors in clinical laboratory and genetic testing diagnostics space
Recent Developments
(February 2026) Posted Q4 2025 results with $148.5M quarterly revenue, $225.7M full-year net loss, and issued 2026 guidance of $530-560M revenue
(February 2026) FDA granted Phase 1 clearance for MDX2301 COVID-19 antibody with BARDA non-dilutive funding
(Q4 2025) Expanded oral PTH partnership with Entera Bio with accelerated IND filing targeted for late 2026
(October 2025) Announced $1B+ value Regeneron partnership for multispecific antibody development
Open the full interactive OPKO Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.